Cohort study of cytomegalovirus infection after rituximab containing-induction chemotherapy and autologous stem cell transplantation for B-cell-Non-Hodgkin's Lymphoma - Cohort study of cytomegalovirus infection after rituximab containing-induction chemotherapy and autologous stem cell transplantation for B-cell-Non-Hodgkin's Lymphoma

Kanazawa university0 个研究点目标入组 30 人开始时间: 2012年12月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•a)Pts received allogeneic hematopoietic(hemopoietic) stem cell transplant or autologous stem cell transplantation greater than two times. b)Pts received rituximab at least 8 weeks before registration. c)Pts received chemotherapy or radiotherapy at least 4 weeks before registration(include induction chemotherapy supported with autologous stem cell transplantation). d)Allergy for monoclonal antibody. e)Pts who observed transformation at relapse. f)Other malignant diseases including simultaneous cancer and disease free state within 5 years after treatment. g)Presense of central nervous invasion(clinical). h)Severe heart failure(New York Heart Association: classIII, IV). i)Severe lung disease. j)Severe infectious disease. k)Positive test for HBs antigen, HCV antibody, HIV antigen, HIV antibody, HBc antibody, HBV-DNA. l)Past history of glaucoma. m)In-treatment diabetes mellitus with insulin. n)Pts who underwent surgery that requires general anesthesia at least 4 weeks before registration. o)Tumor cell>=25,000/mm3. p)Pts are pregnant or lactating women. q)Uncontrol of contraception at during the administration or at least 48 weeks after final dose. r)Psychological disease or psychological symptom that seems to be difficult to partcipate in clinical trial. s)Inadequate for clinical trial entry by the attending physicians.

发起方